Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer

被引:16
作者
Wada, Miku [1 ]
Kukita, Asako [1 ]
Sone, Kenbun [1 ]
Hamamoto, Ryuji [2 ,3 ]
Kaneko, Syuzo [2 ]
Komatsu, Masaaki [2 ,3 ]
Takahashi, Yu [1 ]
Inoue, Futaba [1 ]
Kojima, Machiko [1 ]
Honjoh, Harunori [1 ]
Taguchi, Ayumi [1 ]
Kashiyama, Tomoko [1 ]
Miyamoto, Yuichiro [1 ]
Tanikawa, Michihiro [1 ]
Tsuruga, Tetsushi [1 ]
Mori-Uchino, Mayuyo [1 ]
Wada-Hiraike, Osamu [1 ]
Osuga, Yutaka [1 ]
Fujii, Tomoyuki [1 ]
机构
[1] Univ Tokyo, Dept Obstet & Gynecol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[2] Natl Canc Ctr, Div Mol Modificat & Canc Biol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[3] RIKEN Ctr Adv Intelligence Project, Canc Translat Res Team, Chuo Ku, 1-4-1 Nihonbashi, Tokyo 1030027, Japan
关键词
epigenetic modifier; histone methyltransferase; SETD8; high-grade serous ovarian cancer; UNC0379; HISTONE; METHYLATION; P53; ACTIVATION; EXPRESSION;
D O I
10.3390/biom10121686
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The histone methyltransferase SETD8, which methylates the lysine 20 of histone H4 (H4K20), is reportedly involved in human carcinogenesis along with nonhistone proteins such as p53. However, its expression profiles and functions in the context of high-grade serous ovarian carcinoma (HGSOC) are still unknown. The purpose of this study was to investigate the role of SETD8 in HGSOC. We performed quantitative real-time PCR and immunohistochemistry to detect the expression of SETD8 in HGSOC samples and normal ovarian specimens. Then, we assessed the effect of the inhibition of SETD8 expression using small interfering RNA (siRNA) and a selective inhibitor (UNC0379) on cell proliferation and apoptosis in HGSOC cells. The expression of SETD8 was significantly upregulated in clinical ovarian cancer specimens compared to that in the corresponding normal ovary. In addition, suppression of SETD8 expression in HGSOC cells with either siRNA or UNC0379 resulted in reduced levels of H4K20 monomethylation, inhibition of cell proliferation, and induction of apoptosis. Furthermore, UNC0379 showed a long-term antitumor effect against HGSOC cells, as demonstrated by colony-formation assays. SETD8 thus constitutes a promising therapeutic target for HGSOC, warranting further functional studies.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [41] Genomic Analysis Using Regularized Regression in High-Grade Serous Ovarian Cancer
    Natanzon, Yanina
    Earp, Madalene
    Cunningham, Julie M.
    Kalli, Kimberly R.
    Wang, Chen
    Armasu, Sebastian M.
    Larson, Melissa C.
    Bowtell, David D. L.
    Garsed, Dale W.
    Fridley, Brooke L.
    Winham, Stacey J.
    Goode, Ellen L.
    CANCER INFORMATICS, 2018, 17
  • [42] A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer
    Kreuzinger, Caroline
    Geroldinger, Angelika
    Smeets, Dominiek
    Braicu, Elena Ioana
    Sehouli, Jalid
    Koller, Julia
    Wolf, Andrea
    Darb-Esfahani, Silvia
    Joehrens, Korinna
    Vergote, Ignace
    Vanderstichele, Adriaan
    Boeckx, Bram
    Lambrechts, Diether
    Gabra, Hani
    Wisman, G. Bea A.
    Trillsch, Fabian
    Heinze, Georg
    Horvat, Reinhard
    Polterauer, Stephan
    Berns, Els
    Theillet, Charles
    Castillo-Tong, Dan Cacsire
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 7621 - 7632
  • [43] In vivo modeling of metastatic human high-grade serous ovarian cancer in mice
    Kim, Olga
    Park, Eun Young
    Klinkebiel, David L.
    Pack, Svetlana D.
    Shin, Yong-Hyun
    Abdullaev, Zied
    Emerson, Robert E.
    Coffey, Donna M.
    Kwon, Sun Young
    Creighton, Chad J.
    Kwon, Sanghoon
    Chang, Edmund C.
    Chiang, Theodore
    Yatsenko, Alexander N.
    Chien, Jeremy
    Cheon, Dong-Joo
    Yang-Hartwich, Yang
    Nakshatri, Harikrishna
    Nephew, Kenneth P.
    Behringer, Richard R.
    Fernandez, Facundo M.
    Cho, Chi-Heum
    Vanderhyden, Barbara
    Drapkin, Ronny
    Bast, Robert C., Jr.
    Miller, Kathy D.
    Karpf, Adam R.
    Kim, Jaeyeon
    PLOS GENETICS, 2020, 16 (06):
  • [44] Immune profiling reveals prognostic genes in high-grade serous ovarian cancer
    Wu, Yong
    Xia, Lingfang
    Zhao, Ping
    Deng, Yu
    Guo, Qinhao
    Zhu, Jun
    Chen, Xiaojun
    Ju, Xingzhu
    Wu, Xiaohua
    AGING-US, 2020, 12 (12): : 11398 - 11415
  • [45] Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
    Lee, Sanghoon
    Zhao, Li
    Rojas, Christine
    Bateman, Nicholas W.
    Yao, Hui
    Lara, Olivia D.
    Celestino, Joseph
    Morgan, Margaret B.
    Nguyen, Tri V.
    Conrads, Kelly A.
    Rangel, Kelly M.
    Dood, Robert L.
    Hajek, Richard A.
    Fawcett, Gloria L.
    Chu, Randy A.
    Wilson, Katlin
    Loffredo, Jeremy L.
    Viollet, Coralie
    Jazaeri, Amir A.
    Dalgard, Clifton L.
    Mao, Xizeng
    Song, Xingzhi
    Zhou, Ming
    Hood, Brian L.
    Banskota, Nirad
    Wilkerson, Matthew D.
    Te, Jerez
    Soltis, Anthony R.
    Roman, Kristin
    Dunn, Andrew
    Cordover, David
    Eterovic, Agda Karina
    Liu, Jinsong
    Burks, Jared K.
    Baggerly, Keith A.
    Fleming, Nicole D.
    Lu, Karen H.
    Westin, Shannon N.
    Coleman, Robert L.
    Mills, Gordon B.
    Casablanca, Yovanni
    Zhang, Jianhua
    Conrads, Thomas P.
    Maxwell, George L.
    Futreal, P. Andrew
    Sood, Anil K.
    CELL REPORTS, 2020, 31 (02):
  • [46] Molecular classification and immunologic characteristics of immunoreactive high-grade serous ovarian cancer
    Liu, Zheran
    Wu, Haifang
    Deng, Jiachen
    Wang, Haoqing
    Wang, Zixuan
    Yang, Ailin
    Liang, Bowen
    Luo, Ji
    Li, Jianyong
    Xu, Yanmei
    Tang, Xiaoli
    Fu, Fen
    Deng, Libin
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (14) : 8103 - 8114
  • [47] Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy
    Gronauer, Raphael
    Madersbacher, Leonie
    Monfort-Lanzas, Pablo
    Floriani, Gabriel
    Sprung, Susanne
    Zeimet, Alain Gustave
    Marth, Christian
    Fiegl, Heidelinde
    Hackl, Hubert
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [48] High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment
    Vivod, Gregor
    Merlo, Sebastjan
    Kovacevic, Nina
    CURRENT ONCOLOGY, 2024, 31 (04) : 1920 - 1935
  • [49] In vivo tumor growth of high-grade serous ovarian cancer cell lines
    Mitra, Anirban K.
    Davis, David A.
    Tomar, Sunil
    Roy, Lynn
    Gurler, Hilal
    Xie, Jia
    Lantvit, Daniel D.
    Cardenas, Horacio
    Fang, Fang
    Liu, Yueying
    Loughran, Elizabeth
    Yang, Jing
    Stack, M. Sharon
    Emerson, Robert E.
    Dahl, Karen D. Cowden
    Barbolina, Maria V.
    Nephew, Kenneth P.
    Matei, Daniela
    Burdette, Joanna E.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (02) : 372 - 377
  • [50] Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer
    Adamson, A. W.
    Ding, Y. C.
    Steele, L.
    Leong, L. A.
    Morgan, R.
    Wakabayashi, M. T.
    Han, E. S.
    Dellinger, T. H.
    Lin, P. S.
    Hakim, A. A.
    Wilczynski, S.
    Warden, C. D.
    Tao, S.
    Bedell, V.
    Cristea, M. C.
    Neuhausen, S. L.
    JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)